

Attorney Docket No.: 4366.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schulein et al.

Confirmation No: To be assigned

Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: December 5, 2001

Examiner: To Be Assigned

For: Novel Endoglucanases

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

Before examination, please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claims 2-10, 12-65, 67-83, 87, 88, 90, 92-96 and 101-105 without prejudice or disclaimer.

REMARKS

This amendment is submitted to cancel claims in order to reduce the filing fee. There is no new matter added, and entry of the amendment is respectfully requested.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: December 5, 2001



Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

4366.220-US-1